The saga of the ALS treatment Relyvrio may be generating ripple effects across the disease landscape.
Key Takeaways
-
NeuroSense is adjusting its Phase III trial design in part because of Relyvrio's failure.
-
The plan includes having more control of the investigators and...
Alon Ben-Noon, CEO of NeuroSense Therapeutics Ltd., which is developing PrimeC as an amyotrophic lateral sclerosis treatment, said the company is changing its development program in response to the...